会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
    • 包含不饱和或环状连接基团的杂芳基取代的酰胺及其作为药物的用途
    • US08642620B2
    • 2014-02-04
    • US11958503
    • 2007-12-18
    • Harmut StrobelPaulus WohlfartGerhard ZollerDavid William Will
    • Harmut StrobelPaulus WohlfartGerhard ZollerDavid William Will
    • A61K31/4545C07D401/06
    • C07D401/14C07D401/06C07D401/08C07D409/14C07D417/06
    • The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
    • 本发明涉及式I的N-烷基酰胺,其中A,Het,X,R 1,R 2和R 3具有权利要求中所述的含义,其调节内皮一氧化氮(NO)合酶的转录并且是有价值的药理学 活性化合物。 具体地,式I化合物上调酶内皮NO合成酶的表达,并且可以在需要增加所述酶的表达或增加的NO水平或降低的NO水平的标准化的条件下应用。 本发明还涉及制备式I化合物的方法,包括它们的药物组合物,以及式I化合物在制备用于刺激内皮NO合成酶表达或用于 治疗包括心血管疾病如动脉粥样硬化,血栓形成,冠状动脉疾病,高血压和心功能不全等各种疾病。
    • 9. 发明授权
    • Imidazo[1,2-a]azines and their use as pharmaceuticals
    • 咪唑并[1,2-a]吖嗪及其作为药物的用途
    • US08044050B2
    • 2011-10-25
    • US12548641
    • 2009-08-27
    • Gerhard ZollerHartmut StrobelDavid William WillPaulus Wohlfart
    • Gerhard ZollerHartmut StrobelDavid William WillPaulus Wohlfart
    • A61K31/5025A61K31/519C07D487/04
    • C07D487/04A61K31/4188A61K31/4985A61K31/5025A61K31/519
    • The present invention relates to derivatives of imidazo[1,2-a]azines of formula I, in which R, R1 to R3, X, Y and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of formula I, to pharmaceutical compositions comprising them, and to the use of compounds of formula I for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
    • 本发明涉及式I的咪唑并[1,2-a]吖嗪衍生物,其中R,R 1至R 3,X,Y和n具有权利要求中所示的含义,其调节内皮一氧化氮的转录( NO)合酶,是有价值的药理活性化合物。 具体地,式I化合物上调酶内皮NO合成酶的表达,并且可以在需要增加所述酶的表达或增加的NO水平或降低的NO水平的标准化的条件下使用。 本发明还涉及制备式I化合物的方法,包含它们的药物组合物,以及式I化合物用于刺激内皮NO合成酶表达或用于治疗各种疾病,包括心血管疾病 例如动脉粥样硬化,血栓形成,冠状动脉疾病,高血压和心功能不全。